Suppr超能文献

抗朊蛋白抗体在细胞培养中清除和预防朊病毒感染

Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

作者信息

Pankiewicz Joanna, Prelli Frances, Sy Man-Sun, Kascsak Richard J, Kascsak Regina B, Spinner Daryl S, Carp Richard I, Meeker Harry C, Sadowski Marcin, Wisniewski Thomas

机构信息

Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

出版信息

Eur J Neurosci. 2006 May;23(10):2635-47. doi: 10.1111/j.1460-9568.2006.04805.x.

Abstract

Prion diseases are transmissible and invariably fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP(C)) into a self-replicating and proteinase K (PK)-resistant conformer, scrapie PrP (PrP(Sc)). Humoral immunity may significantly prolong the incubation period and even prevent disease in murine models of prionoses. However, the mechanism(s) of action of anti-PrP monoclonal antibodies (Mabs) remain(s) obscure. The murine neuroblastoma N2a cell line, infected with the 22L mouse-adapted scrapie strain, was used to screen a large library of Mabs with similar binding affinities to PrP, to identify those antibodies which could clear established infection and/or prevent infection de novo. Three Mabs were found capable of complete and persistent clearing of already-infected N2a cells of PrP(Sc). These antibodies were 6D11 (generated to PK-resistant PrP(Sc) and detecting PrP residues 93-109), and 7H6 and 7A12, which were raised against recombinant PrP and react with neighbouring epitopes of PrP residues 130-140 and 143-155, respectively. Mabs were found to interact with PrP(Sc) formation both on the cell surface and after internalization in the cytosol. Treatment with Mabs was not associated with toxicity nor did it result in decreased expression of PrP(C). Both preincubation of N2a cells with Mabs prior to exposure to 22L inoculum and preincubation of the inoculum with Mabs prior to infecting N2a cells resulted in a significant reduction in PrP(Sc) levels. Information provided in these studies is important for the rational design of humoral immune therapy for prion infection in animals and eventually in humans.

摘要

朊病毒病是可传播的、 invariably fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP(C)) into a self-replicating and proteinase K (PK)-resistant conformer, scrapie PrP (PrP(Sc)). Humoral immunity may significantly prolong the incubation period and even prevent disease in murine models of prionoses. However, the mechanism(s) of action of anti-PrP monoclonal antibodies (Mabs) remain(s) obscure. The murine neuroblastoma N2a cell line, infected with the 22L mouse-adapted scrapie strain, was used to screen a large library of Mabs with similar binding affinities to PrP, to identify those antibodies which could clear established infection and/or prevent infection de novo. Three Mabs were found capable of complete and persistent clearing of already-infected N2a cells of PrP(Sc). These antibodies were 6D11 (generated to PK-resistant PrP(Sc) and detecting PrP residues 93-109), and 7H6 and 7A12, which were raised against recombinant PrP and react with neighbouring epitopes of PrP residues 130-140 and 143-155, respectively. Mabs were found to interact with PrP(Sc) formation both on the cell surface and after internalization in the cytosol. Treatment with Mabs was not associated with toxicity nor did it result in decreased expression of PrP(C). Both preincubation of N2a cells with Mabs prior to exposure to 22L inoculum and preincubation of the inoculum with Mabs prior to infecting N2a cells resulted in a significant reduction in PrP(Sc) levels. Information provided in these studies is important for the rational design of humoral immune therapy for prion infection in animals and eventually in humans. (注:原文中“invariably fatal neurodegenerative disorders”未准确翻译,可改为“不可避免的致命性神经退行性疾病” ;“react with neighbouring epitopes”可改为“与相邻表位反应” 。整体译文存在较多专业术语翻译不准确或表述不清晰的问题,建议进一步核对专业词汇并优化表述。)

朊病毒病是可传播的、不可避免的致命性神经退行性疾病,与细胞朊蛋白(PrP(C))构象转变为自我复制且对蛋白酶K(PK)具有抗性的异构体——瘙痒病朊蛋白(PrP(Sc))有关。在朊病毒病的小鼠模型中,体液免疫可能会显著延长潜伏期,甚至预防疾病。然而,抗PrP单克隆抗体(Mab)的作用机制仍不清楚。用适应小鼠的22L瘙痒病毒株感染的小鼠神经母细胞瘤N2a细胞系,用于筛选大量与PrP具有相似结合亲和力的单克隆抗体库,以鉴定那些能够清除已建立的感染和/或从头预防感染的抗体。发现三种单克隆抗体能够完全且持续地清除已感染PrP(Sc)的N2a细胞。这些抗体是6D11(针对抗蛋白酶K的PrP(Sc)产生,检测PrP残基93 - 109),以及7H6和7A12,它们是针对重组PrP产生的,分别与PrP残基130 - 140和143 - 155的相邻表位反应。发现单克隆抗体在细胞表面以及内化到细胞质后均与PrP(Sc)的形成相互作用。用单克隆抗体治疗与毒性无关,也不会导致PrP(C)表达降低。在暴露于22L接种物之前用单克隆抗体预孵育N2a细胞,以及在感染N2a细胞之前用单克隆抗体预孵育接种物,均导致PrP(Sc)水平显著降低。这些研究中提供的信息对于合理设计针对动物乃至人类朊病毒感染的体液免疫疗法很重要。

相似文献

1
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.
Eur J Neurosci. 2006 May;23(10):2635-47. doi: 10.1111/j.1460-9568.2006.04805.x.
3
Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
J Neurochem. 2004 Apr;89(2):454-63. doi: 10.1111/j.1471-4159.2004.02356.x.
5
Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity.
J Biol Chem. 2012 Apr 13;287(16):12858-66. doi: 10.1074/jbc.M111.255836. Epub 2012 Feb 23.
8
Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice.
Hybrid Hybridomics. 2003 Aug;22(4):263-6. doi: 10.1089/153685903322328992.

引用本文的文献

1
Prion protein E219K polymorphism: from the discovery of the KANNO blood group to interventions for human prion disease.
Front Neurol. 2024 Jul 10;15:1392984. doi: 10.3389/fneur.2024.1392984. eCollection 2024.
2
Prion therapeutics: Lessons from the past.
Prion. 2022 Dec;16(1):265-294. doi: 10.1080/19336896.2022.2153551.
3
Treatment of microglia with Anti-PrP monoclonal antibodies induces neuronal apoptosis .
Heliyon. 2021 Dec 21;7(12):e08644. doi: 10.1016/j.heliyon.2021.e08644. eCollection 2021 Dec.
6
Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology.
Front Aging Neurosci. 2021 Feb 25;13:640677. doi: 10.3389/fnagi.2021.640677. eCollection 2021.
7
The role of prion strain diversity in the development of successful therapeutic treatments.
Prog Mol Biol Transl Sci. 2020;175:77-119. doi: 10.1016/bs.pmbts.2020.07.001. Epub 2020 Aug 28.
8
Protective anti-prion antibodies in human immunoglobulin repertoires.
EMBO Mol Med. 2020 Sep 7;12(9):e12739. doi: 10.15252/emmm.202012739. Epub 2020 Aug 10.
9
Immunotherapy against Prion Disease.
Pathogens. 2020 Mar 14;9(3):216. doi: 10.3390/pathogens9030216.
10
A Bioluminescent Cell Assay to Quantify Prion Protein Dimerization.
Sci Rep. 2018 Sep 21;8(1):14178. doi: 10.1038/s41598-018-32581-1.

本文引用的文献

1
SPONGIFORM DISEASE: Experts Downplay New vCJD Fears.
Science. 2000 Sep 8;289(5485):1663b-6b. doi: 10.1126/science.289.5485.1663b.
2
Mucosal vaccination delays or prevents prion infection via an oral route.
Neuroscience. 2005;133(2):413-21. doi: 10.1016/j.neuroscience.2005.02.031.
3
GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion.
Oncogene. 2005 Mar 3;24(10):1673-82. doi: 10.1038/sj.onc.1208395.
4
Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.
J Biol Chem. 2005 Mar 25;280(12):11247-58. doi: 10.1074/jbc.M407006200. Epub 2004 Dec 23.
6
Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.
J Gen Virol. 2004 Nov;85(Pt 11):3473-3482. doi: 10.1099/vir.0.80113-0.
9
Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.
Lancet. 2004;364(9433):527-9. doi: 10.1016/S0140-6736(04)16811-6.
10
Targeting prion amyloid deposits in vivo.
J Neuropathol Exp Neurol. 2004 Jul;63(7):775-84. doi: 10.1093/jnen/63.7.775.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验